Portfolio company
Excision Biotherapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This biotechnology company develops CRISPR-based gene editing therapies designed to cure chronic viral infectious diseases for patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
EDITAS Medicine
The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.
Precision BioSciences
This company develops in vivo gene editing therapies for patients with genetic and infectious diseases using its proprietary ARCUS genome editing platform.
Akribion Therapeutics
The company develops RNA-guided nuclease technology for programmable cell depletion to treat cancer and autoimmune diseases for healthcare providers and patients.
Agenovir
This company develops nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes for healthcare providers treating patients with persistent viral infections.
Beam Therapeutics
The company develops precision genetic medicines using base editing technology to treat patients with serious genetic diseases such as sickle cell disease.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
Asher Biotherapeutics
This biotechnology company develops targeted immunotherapies for patients with cancer, infectious diseases and autoimmune conditions.
Eradivir
This biotechnology company develops small molecule immunotherapies that target viral infections and cancers for healthcare providers and patients.